Respiratory:  Baby [**Name (NI) **] [**Known lastname 406**] is currently intubated and ventilated with chronic lung disease status post hyaline membrane disease.
As detailed in his previous transfer summary, he received two doses of surfactant subsequent to delivery and has since that time developed chronic lung disease.
He is currently on conventional ventilation with SIMV settings of 23/6 with a rate of 34.
He has not received a blood gas since that time, however, his settings have remained stable.
His current respiratory medications are Combivent two puffs q.
and chlorothiazide 40 mg/kg/day divided b.i.d.
Fluids, Electrolytes and Nutrition:  Since Baby [**Name (NI) **] [**Known lastname 35160**] last dictation on [**2173-4-19**], he has remained on full feeds at 140 cc/kg/day of Preemie Enfamil 30 calorie/ounce or mother's milk fortified to 30 calories per ounce.
His diet is supplemented with sodium chloride at 4 mEq/kg/day, potassium chloride at approximately 1 mEq/kg/day, iron and vitamins.
His thigh appeared to be cellulitic and, as such, he was started on oxacillin intravenously.
A CBC was obtained, as well, on [**2173-5-4**], and was significant for a rising white blood cell count of 24,300 with a differential of 54 segs and 7 bands without immature cells.
Follow up on this culture today, [**2173-5-4**], was unchanged with speciation and sensitivities being set up today.
Infectious Disease consultation was obtained and the recommendation was for a broadening of coverage to vancomycin, gentamicin and oxacillin.
The ultrasound was significant for the finding of a significant fluid pocket over the hip joint which was not possible to penetrate through to see the actual hip joint itself.
Broadened coverage including vancomycin and gentamicin will be initiated prior to transfer to the [**Hospital3 1810**].
Endocrine:  Baby [**Name (NI) **] [**Known lastname 406**] has remained on Synthroid therapy secondary to newborn state screening revealing hypothyroidism.
He is currently on Synthroid at 6.25 mcg p.o.
